Abstract
The effects of various opioid receptor agonists and antagonists on evoked acetylcholine release were studied in slices of human neocortex prelabelled with [3H]-choline, superfused and depolarized electrically (2 min, 3 Hz, 2 ms, 24 mA) or by K+ (20 mM). The δ-opioid receptor agonist DPDPE and the κ-opioid receptor agonist U50488 reduced the evoked [3H]-overflow (acetylcholine release) in a concentration-dependent fashion; the δ-opioid receptor antagonist naltrindole and the the κ-opioid receptor antagonist norbinaltorphimine, respectively, antagonized these effects. Application of the μ-opioid receptor agonist DAGO also resulted in an inhibition of acetylcholine release; however, both δ- and κ-opioid receptor antagonists were able to block this effect. The μ-opioid receptor agonists morphine and (+)-nortilidine had no effect. These results indicate that acetylcholine release in human neocortex is inhibited through δ- and κ-opioid receptors, but not through μ-opioid receptors.
Acetylcholine release was significantly increased by the δ-opioid receptor antagonist naltrindole in the presence of a mixture of peptidase inhibitors providing evidence for a δ-opioid receptor-mediated inhibition of acetylcholine release by endogenous enkephalin.
K+-evoked acetylcholine release in the presence of TTX was inhibited by U50488, but not by DPDPE, suggesting the presence of κ-opioid receptors on cholinergic terminals and the localization of δ-receptors on cortical interneurons. Therefore, the potent effect of DPDPE on acetylcholine release is likely to be indirect, by modulation of intrinsic cortical neurons. These interneurons probably do not use GABA as neurotransmitter since both GABAA and GABAB receptor agonists (muscimol and baclofen, respectively) were without effect on acetylcholine release.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Anger WK (1991) Animal test systems to study behavioral dysfunctions of neurodegenerative disorders. Neurotoxicology 12:403–413
Birch PJ, Hayes AG, Sheehan MJ, Tyers MB (1987) Norbinaltorphimine: antagonist profile at κ opioid receptors. Eur J Pharmacol 144:405–408
Clark JA, Itzhak Y, Hruby VJ, Yamamura HI, Pasternak GW (1986) [D-Pen2,D-Pen5]enkephalin (DPDPE): a δ-selective enkephalin with low affinity for m1 opiate binding sites. Eur J Pharmacol 128:303–304
Coyle JT, Price DL, DeLong MR (1983) Alzheimer's disease: a disorder of cortical cholinergic innervation. Science 219:1184–1190
Deuchars J, Thomson AM (1995) Single axon fast inhibitory postsynaptic potentials elicited by a sparsely spiny interneuron in rat neocortex. Neuroscience 65:935–942
Domino EF (1979) Opiate interactions with cholinergic neurons. Adv Biochem Psychopharmacol 20:339–355
Evans CJ, Keith DJ, Morrison H, Magendzo K, Edwards RH (1992) Cloning of a δ opioid receptor by functional expression. Science 258:1952–1955
Feuerstein TJ, Bammert J, Meyer DK (1987) Endogenous agonists may change the concentration-response curves of exogenous agonists: source of quantitative information about the endogenous tone. Biol Cybernetics 56:419–429
Feuerstein TJ, Dooley DJ, Seeger W (1990) Inhibition of norepinephrine and acetylcholine release from human neocortex by ω-conotoxin GVIA. J Pharmacol Exp Ther 252:778–785
Feuerstein TJ, Neuschwander E, Sauermann W, Lupp A (1991) The conditions of Ca2+ entry via L-type channels for induction of serotonin release from rabbit hippocampus. Eur J Pharmacol 198:37–42
Feuerstein TJ, Lehmann J, Sauermann W v. Velthoven V, Jackisch R (1992) The autoinhibitory feedback control of acetylcholine release from human neocortex tissue. Brain Res 572:64–71
Feuerstein TJ, Mutschler A, Lupp A, v. Velthoven V, Schlicker E, Göthert M (1993) Endogenous noradrenaline activates α2-adrenoceptors on serotonergic nerve endings in human and rat neocortex. J Neurochem 61:474–480
Feuerstein TJ, Sauermann W, Allgaier C, Agneter E, Singer EA (1994) New insights into receptor theory, as provided by an artificial partial agonist made-to-measure. Naunyn-Schmiedeberg's Arch Pharmacol 350:1–9
Goldstein A, Naidu A (1989) Multiple opioid receptors: ligand selectivity profiles and binding site signatures. Mol Pharmacol 36:265–272
Izquierdo I (1990) Acetylcholine release is modulated by different opioid receptor types in different brain regions and species. Trends Pharmacol Sci 11:179–180
Jackisch R (1991) Regulation of neurotransmitter release by opiates and opioid peptides in the central nervous system. In: Feigenbaum J, Hanani M (eds) Presynaptic regulation of neurotransmitter release: a handbook, Freund, Tel Aviv, pp 551–592
Jackisch R, Geppert M, Brenner AS, Illes P (1986) Presynaptic opioid receptors modulating acetylcholine release in the hippocampus of the rabbit. Naunyn-Schmiedeberg's Arch Pharmacol 332:156–162
Jackisch R, Hotz H, Hertting G (1993) No evidence for presynaptic opioid receptors on cholinergic, but presence of κ-receptors on dopaminergic neurons in the rabbit caudate nucleus: involvement of endogenous opioids. Naunyn Schmiedeberg's Arch Pharmacol 348:234–241
Kieffer BL, Befort K, Gaveriaux RC, Hirth CG (1994) The δ-opioid receptor: Isolation of a cDNA by expression cloning and pharmacological characterization. Proc Natl Acad Sci USA 91:12048–12052
Kosterlitz HW Paterson SJ, Robson LE, Traynor JR (1987) Effects of cations on binding, in membrane suspensions, of various opioids at m-sites of rabbit cerebellum and k-sites of guinea-pig cerebellum. Br J Pharmacol 91:431–437
Lapchak PA, Araujo DM, Collier B (1989) Regulation of endogenous acetylcholine release from mammalian brain slices by opiate receptors: hippocampus, striatum and cerebral cortex of guinea-pig and rat. Neuroscience 31:313–325
Leslie FM (1987) Methods used for the study of opioid receptors. Pharmacol Rev 39:197–249
McGaugh JL (1989) Involvement of hormonal and neuromodulatory systems in the regulation of memory storage. Annu Rev Neurosci 12:255–287
Paterson SJ, Robson LE, Kosterlitz HW (1983) Classification of opioid receptors. Br Med Bull 39:31–36
Portoghese PS, Sultana M, Takemori AE (1988) Naltrindole, a highly selective and potent non-peptide d-opioid receptor antagonist. Eur J Pharmacol 146:185–186
Rogers H, Hayes AG, Birch PJ, Traynor JR, Lawrence AJ (1990) The selectivity of the opioid antagonist, naltrindole, for d-opioid receptors. J Pharm Pharmacol 42:358–359
Sanger DJ, Joly D (1990) Psychopharmacological strategies in the search for cognition enhancers. Pharmacopsychiatry 2:70–74
Schulz R, Blasig J, Wuster M, Herz A (1978) The opiate-like action of tilidine is mediated by metabolites. Naunyn-Schmiedeberg's Arch Pharmacol 304:89–93
Takemori AE, Ho BY, Naeseth JS, Portoghese PS (1988) Nor-binaltorphimine, a highly selective k-opioid antagonist in analgesic and receptor binding assays. J Pharmacol Exp Ther 246:255–258
Taquet H, Javoy AF, Mauborgne A, Benoliel JJ, Agid Y, Legrand JC, Tramu G, Cesselin F, Hamon M (1988) Biochemical mapping of cholecystokinin-, substance P-, [Met]enkephalin-, [Leu]enkephalin-and dynorphin A (1–8)-like immunoreactivities in the human cerebral cortex. Neuroscience 27:871–883
Thompson RC, Mansour A, Akil H, Watson SJ (1993) Cloning and pharmacological characterization of a rat m-opioid receptor. Neuron 11:903–913
Turner AJ, Matsas R, Kenny AJ (1985) Are there neuropeptide-specific peptidases? Biochem Pharmacol 34:1347–1356
Vonvoigtlander PF, Lahti RA, Ludens JH (1983) U-50,488: a selective and structurally novel non-μ (k) opioid agonist. J Pharmacol Exp Ther 224:7–12
Westlake WJ (1981) Response to bioequivalence testing — a need to rethink. Biometrics 37:591–593
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Feuerstein, T.J., Gleichauf, O., Peckys, D. et al. Opioid receptor-mediated control of acetylcholine release in human neocortex tissue. Naunyn-Schmiedeberg's Arch Pharmacol 354, 586–592 (1996). https://doi.org/10.1007/BF00170832
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00170832